Brick & Kyle Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Brick & Kyle Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-200	Closed	-$29K	–	230
2017 Q1	$29K	Hold	200	–	–	0.02%	232
2016 Q4	$22K	Hold	200	–	–	0.02%	268
2016 Q3	$24K	Hold	200	–	–	0.02%	251
2016 Q2	$28K	Hold	200	–	–	0.02%	228
2016 Q1	$26K	Hold	200	–	–	0.02%	226
2015 Q4	$28K	Hold	200	–	–	0.02%	212
2015 Q3	$27K	Hold	200	–	–	0.03%	224
2015 Q2	$35K	Hold	200	–	–	0.03%	210
2015 Q1	$35K	Sell	200 -150	-43%	-$25.7K	0.03%	213
2014 Q4	$57K	Buy	+350	New	+$58.1K	0.05%	166

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Brick & Kyle Associates's JAZZ Position: Q2 2017 in Review

Brick & Kyle Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2017, closing a stake of 200 shares — an estimated $29K sold.

Brick & Kyle Associates first reported a position in JAZZ in Q4 2014 and held it in 10 quarters. The position peaked at $57K in Q4 2014. 319 funds tracked by Wall St. Rank hold JAZZ as of Q2 2017.

Brick & Kyle Associates reported no remaining Jazz Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Brick & Kyle Associates sold 200 Jazz Pharmaceuticals shares in Q2 2017, an estimated $29K.
Brick & Kyle Associates first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Brick & Kyle Associates's Jazz Pharmaceuticals position peaked at $57K in Q4 2014.
319 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2017.

Based on Brick & Kyle Associates's 13F filing for Q2 2017, filed 14 Aug 2017.